-transparent.png){kind=logo}
Various 5-substituted 2'-deoxycytidines, including 5-bromo-dCyd, 5-iodo-dCyd, 5-nitro-dCyd, 5-ethynyl-dCyd, 5-propyl-dCyd, (E)-5-(2-bromovinyl)-dCyd, and (E)-5-(2-iodovinyl)-dCyd, were evaluated for their antiviral and antimetabolic properties in primary rabbit kidney (PRK) cell cultures and for their inhibitory effects on murine L1210 cell proliferation. All dCyd analogues proved to be selective inhibitors of herpes simplex virus (HSV) replication: 5-bromo-dCyd, 5-iodo-dCyd, 5-nitro-dCyd, and 5-ethynyl-dCyd were more selective in their anti-HSV activity than were the corresponding 5-substituted 2'-deoxyuridines, whereas 5-propyl-dCyd, (E)-5-(2-bromovinyl)-dCyd, and (E)-5-(2-iodovinyl)-dCyd were as selective as their dUrd counterparts. The dCyd analogues were also less cytotoxic (for both PRK and L1210 cells), as could be monitored by inhibition of either cell proliferation or host-cell DNA synthesis (incorporation of radiolabeled precursors). Of all 5-substituted 2'-deoxycytidines tested, the (E)-5-(2-halogenovinyl) derivatives emerged as the most potent and most selective inhibitors of HSV (Type 1) replication.
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
July 1985,
Antimicrobial agents and chemotherapy,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
October 1980,
Methods and findings in experimental and clinical pharmacology,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
March 1985,
Journal of pharmaceutical sciences,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
September 1997,
Bollettino chimico farmaceutico,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
January 1987,
Nucleic acids symposium series,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
June 1978,
Biochemical and biophysical research communications,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
October 1975,
Biochemical pharmacology,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
January 1979,
Voprosy virusologii,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
November 1979,
Biochemical pharmacology,
E De Clercq, and
J Balzarini, and
J Descamps, and
G F Huang, and
P F Torrence, and
D E Bergstrom, and
A S Jones, and
P Serafinowski, and
G Verhelst, and
R T Walker
November 1982,
Il Farmaco; edizione scientifica,
